journal

Dr. Robin Carhart-Harris, a distinguished professor of neurology and psychiatry at the University of California, San Francisco, has been at the forefront of a groundbreaking research trajectory, exploring the enigmatic realm of psychedelics. He sits at the helm of studies investigating how drugs like psilocybin, popularly known as magic mushrooms, can ameliorate major depression symptoms in over 67% of users.

In a recent podcast Huberman Lab podcast, Dr. Carhart-Harris divulged insights into the intricacies of the history, laws, and working mechanisms of psychedelics. At the heart of his lab’s quest is the goal to understand how these substances, under the right medical supervision, can stimulate neuroplasticity, rewiring the brain to augment facets of the human mind, including creativity and intelligence.

As is often the case, the human mind tends to hide its most fascinating workings beneath the surface. For instance, blindsight, a curious phenomenon where blind individuals can accurately guess the number of dots on a screen, exposes a covert facet of our mind. Similarly, psychedelic substances such as LSD and psilocybin, have been found to reveal intricate workings of the mind that remain usually hidden – a process described as “psyche revealing.”

Psychedelic therapy, a promising avenue currently being explored, incorporates the controlled use of substances like psilocybin to alleviate conditions like depression. A key principle of such a therapeutic process is the patient’s capacity to ‘let go’ and trust the mental health professionals involved. This trusting relationship has been found to significantly affect the quality of the experience and the therapeutic outcomes.

Remarkable results have been documented in studies examining the use of psilocybin for chronic pain disorders, such as fibromyalgia. Researchers have found that guiding patients to ‘listen to their inner healer,’ rather than focusing on pain, leads to extraordinary improvements. Yet, despite these advancements, the use of LSD in clinical trials remains limited due to the extended duration of its effects.

Dr. Carhart-Harris advocates the exploration of psychedelics, not as standalone treatments but as supplements to existing treatment modalities. He warns of potential malpractices in psychedelic therapy, highlighting the need for safeguards and high standards in this rapidly developing field.

As the field navigates the intricate labyrinth of legality, the future of psychedelic therapy shines brightly. With MDMA and psilocybin currently in phase three trials, their expected approval in the coming years signals a massive leap towards the legal prescription of psychedelic medicines for disorders such as depression, anorexia, fibromyalgia, trauma, and addiction.

Although Western science initially brushed off psychedelics as countercultural and eccentric, a surge of quality studies now illuminate their potential therapeutic benefits. As Dr. Carhart-Harris sagely advises, “we must challenge the current system of treatments and explore the potential of psychedelics while doing the work properly.” The research community is now primed to bring about a paradigm shift in our understanding and treatment of mental health disorders using these enigmatic substances.

Sources:

https://podcasts.apple.com/us/podcast/huberman-lab/id1545953110?i=1000613957683

* Nue Life Health is leveraging the power of Nue Life’s AI knowledge engine to produce informative personal wellness articles, which are carefully reviewed and fact-checked by our team of experienced editors.

‍